These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 34192550)
1. Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Batis N; Brooks JM; Payne K; Sharma N; Nankivell P; Mehanna H Adv Drug Deliv Rev; 2021 Sep; 176():113854. PubMed ID: 34192550 [TBL] [Abstract][Full Text] [Related]
3. How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy. Mankoff DA; Farwell MD; Clark AS; Pryma DA Cancer J; 2015; 21(3):218-24. PubMed ID: 26049702 [TBL] [Abstract][Full Text] [Related]
5. Cancer biomarker discovery and translation: proteomics and beyond. Hristova VA; Chan DW Expert Rev Proteomics; 2019 Feb; 16(2):93-103. PubMed ID: 30556752 [TBL] [Abstract][Full Text] [Related]
6. Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. Ow TJ; Sandulache VC; Skinner HD; Myers JN Cancer; 2013 Nov; 119(22):3914-28. PubMed ID: 24037788 [TBL] [Abstract][Full Text] [Related]
7. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X; Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236 [TBL] [Abstract][Full Text] [Related]
8. The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer. Ros J; Baraibar I; Martini G; Salvà F; Saoudi N; Cuadra-Urteaga JL; Dienstmann R; Tabernero J; Élez E Curr Treat Options Oncol; 2021 Nov; 22(12):113. PubMed ID: 34741675 [TBL] [Abstract][Full Text] [Related]
9. Preface on application of omics technologies in cancer biology and therapy. Georgakilas AG Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153 [No Abstract] [Full Text] [Related]
10. Extracellular vesicles as biomarkers and therapeutic targets for cancer. Urabe F; Kosaka N; Ito K; Kimura T; Egawa S; Ochiya T Am J Physiol Cell Physiol; 2020 Jan; 318(1):C29-C39. PubMed ID: 31693397 [TBL] [Abstract][Full Text] [Related]
11. A Detailed Catalogue of Multi-Omics Methodologies for Identification of Putative Biomarkers and Causal Molecular Networks in Translational Cancer Research. Vlachavas EI; Bohn J; Ückert F; Nürnberg S Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802234 [TBL] [Abstract][Full Text] [Related]
12. Status of Immune Oncology: Challenges and Opportunities. Cesano A; Marincola FM; Thurin M Methods Mol Biol; 2020; 2055():3-21. PubMed ID: 31502145 [TBL] [Abstract][Full Text] [Related]
13. From integrative genomics to therapeutic targets. Natrajan R; Wilkerson P Cancer Res; 2013 Jun; 73(12):3483-8. PubMed ID: 23740772 [TBL] [Abstract][Full Text] [Related]
14. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Berry DA; Herbst RS; Rubin EH Clin Cancer Res; 2012 Feb; 18(3):638-44. PubMed ID: 22298897 [TBL] [Abstract][Full Text] [Related]
15. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care. Marshall JL Oncology (Williston Park); 2020 Sep; 34(9):356-357. PubMed ID: 32965666 [No Abstract] [Full Text] [Related]
16. Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial. Lee J; Kim ST; Kim K; Lee H; Kozarewa I; Mortimer PGS; Odegaard JI; Harrington EA; Lee J; Lee T; Oh SY; Kang JH; Kim JH; Kim Y; Ji JH; Kim YS; Lee KE; Kim J; Sohn TS; An JY; Choi MG; Lee JH; Bae JM; Kim S; Kim JJ; Min YW; Min BH; Kim NKD; Luke S; Kim YH; Hong JY; Park SH; Park JO; Park YS; Lim HY; Talasaz A; Hollingsworth SJ; Kim KM; Kang WK Cancer Discov; 2019 Oct; 9(10):1388-1405. PubMed ID: 31315834 [TBL] [Abstract][Full Text] [Related]
17. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. Middleton G; Crack LR; Popat S; Swanton C; Hollingsworth SJ; Buller R; Walker I; Carr TH; Wherton D; Billingham LJ Ann Oncol; 2015 Dec; 26(12):2464-9. PubMed ID: 26410619 [TBL] [Abstract][Full Text] [Related]
18. Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Esmail LC; Roth J; Rangarao S; Carlson JJ; Thariani R; Ramsey SD; Veenstra DL; Deverka P Genet Med; 2013 Feb; 15(2):115-22. PubMed ID: 23037935 [TBL] [Abstract][Full Text] [Related]
19. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine. Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133 [TBL] [Abstract][Full Text] [Related]
20. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Syn NL; Yong WP; Goh BC; Lee SC Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):911-22. PubMed ID: 27249175 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]